Is Pegasys used for chronic Hepatitis B mono-therapy?

Is Pegasys (peginterferon alfa-2a) used as a single-drug treatment for chronic hepatitis B?

Pegasys is an interferon-based therapy used in hepatitis B treatment, including regimens used as mono-therapy for chronic hepatitis B. The key point for mono-therapy is that it can be prescribed without combining it with another hepatitis B antiviral in the treatment plan.

When would clinicians choose Pegasys instead of combination therapy?

Pegasys mono-therapy is generally considered in patients where interferon-based treatment is appropriate and where clinicians aim to use a single agent rather than combination antiviral therapy. Practical selection depends on factors such as disease activity (e.g., hepatitis B viral markers and liver status) and patient-specific considerations.

Does mono-therapy apply to all chronic hepatitis B patients?

No. Treatment choice in chronic hepatitis B depends on patient and disease characteristics, and Pegasys may be used differently across populations. Some patients are managed with nucleos(t)ide analogs or other regimens instead, and the “best” approach varies by clinical scenario.

Sources

No sources were provided with your question, and I don’t have any reference material here to verify Pegasys’s specific mono-therapy labeling or indications for chronic hepatitis B in the exact jurisdiction you care about. If you tell me the country/label (for example, FDA/US prescribing information vs. EMA/EU vs. another country), I can answer more precisely.